β-Site APP-cleaving enzyme 1 (BACE1) inhibition is considered one of the most promising therapeutic strategies for Alzheimer’s disease, but current BACE1 inhibitors also block BACE2. The gene discussed is BACE2; the disease is early-onset autosomal dominant Alzheimer disease.